Mainstay Medical
Mainstay Medical is developing ReActiv8, an implantable peripheral nerve stimulator system leveraging a novel neurorehabilitation therapy approach to treat chronic, non-specific, low back pain. Chronic low back pain is a major unmet medical problem afflicting millions of people world-wide each year, where conventional therapies have limited effectiveness for the majority of patients. Both the Capital Fund and the Crossover Fund have invested in Mainstay.
Sector
Medical Devices
Strategies
Capital & Crossover
Status
Active
Website
mainstaymedical.com
Related Articles
Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
Mainstay Medical Announces Reimbursement Approval for ReActiv8 in Australia
Mainstay Medical Announces Positive Outcome of Interim Analysis
Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain in Ireland
Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.